HIV-1 rational vaccine design: molecular details of b12–gp120 complex structure

References

• Zhou T, Xu L, Dey B et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature445(7129), 732–737 (2007).
   PubMed Web of Science ®Google Scholar
• Burton DR, Barbas CF 3rd, Persson MA et al. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl Acad. Sci. USA88(22), 10134–10137 (1991).
   PubMed Web of Science ®Google Scholar
• Burton DR, Pyati J, Koduri R et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science266(5187), 1024–1027 (1994).
   PubMed Web of Science ®Google Scholar
• Parren PW, Ditzel HJ, Gulizia RJ et al. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS9(6), F1–F6 (1995).
   PubMed Web of Science ®Google Scholar
• Posner MR, Cavacini LA, Emes CL et al. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J. Acquir. Immune Defic. Syndr.6(1), 7–14 (1993).
   PubMed Web of Science ®Google Scholar
• Roben P, Moore JP, Thali M et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol.68(8), 4821–4828 (1994).
   PubMed Web of Science ®Google Scholar
• Pantophlet R, Ollmann Saphire E, Poignard P et al. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol.77(1), 642–658 (2003).
   PubMed Web of Science ®Google Scholar
• Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA102(42), 14943–14948 (2005).
   PubMed Web of Science ®Google Scholar
• Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol.5(3), 233–236 (2004).
   PubMed Web of Science ®Google Scholar
• Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell124(4), 677–681 (2006).
   PubMed Web of Science ®Google Scholar
• Phogat S and Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des.13(2), 213–227 (2007).
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Igarashi T, Haigwood NL et al. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl Acad. Sci. USA100(25), 15131–15136 (2003).
   PubMed Web of Science ®Google Scholar
• Veazey RS, Shattock RJ, Pope M et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med.9(3), 343–346 (2003).
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med.6(2), 207–210 (2000).
   PubMed Web of Science ®Google Scholar
• Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.J. Virol.75(17), 8340–8347 (2001).
   PubMed Web of Science ®Google Scholar
• Ofek G, Tang M, Sambor A et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol.78(19), 10724–10737 (2004).
   PubMed Web of Science ®Google Scholar
• Cardoso RM, Brunel FM, Ferguson S et al. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J. Mol. Biol.365(5), 1533–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Cardoso RM, Zwick MB, Stanfield RL et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity22(2), 163–173 (2005).
   PubMed Web of Science ®Google Scholar
• Calarese DA, Lee HK, Huang CY et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl Acad. Sci. USA102(38), 13372–13377 (2005).
   PubMed Web of Science ®Google Scholar
• Calarese DA, Scanlan CN, Zwick MB et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science300(5628), 2065–2071 (2003).
   PubMed Web of Science ®Google Scholar